Goldman Sachs Raises Henry Schein PT To $67, Maintains Neutral (HSIC)

Goldman Sachs raised its Henry Schein HSIC price target from $60 to $67 and kept its Neutral rating in a research report published today. In the report, Goldman Sachs states, "While we do not believe the North American dental market has returned to historical growth levels, we see these results as a positive indicator that things are on the right track. In addition, we view the International (up 4.0% internally) and Medical segments (up 7.1% ex-flu) performance as supportive of overall improving environments." Shares of Henry Schein were trading at $67.41 at the time of posting, up 0.73% from Tuesday's market close.